- Innovent Biologics (IVBIY, Financial) achieved an MSCI ESG rating of AAA, distinguishing it as the only biotech in China and one of three globally with such recognition.
- 15 commercialized products of Innovent have benefited 5 million patients, with 3 NDAs under review and 19 molecules in development.
- Innovent's ongoing expansion will increase their production capacity from 140,000L to 230,000L.
Innovent Biologics (IVBIY) has released its 2024 ESG Report, underscoring its commitment to sustainable development and innovation. The company distinguished itself by achieving an MSCI ESG rating of AAA, marking it as the sole biotech in China with this rating and one of only three globally.
Key achievements in 2024 include the commercialization of 15 products, benefiting over 5 million patients. Innovent continues to grow its robust pipeline with 3 New Drug Applications (NDAs) currently under review and 19 molecules in various stages of development. The company has also secured inclusion for 6 of its medicines in China's National Reimbursement Drug List (NRDL), thereby improving drug affordability for patients.
The company's production capacity currently stands at 140,000 liters, spread across facilities in Suzhou and Hangzhou. Plans are underway to expand the capacity to 230,000 liters, with an additional 90,000 liters under development at the Hangzhou site.
Innovent has also made significant strides in environmental stewardship, achieving a 29% reduction in energy consumption and a 22% reduction in fresh water use per unit of production compared to the previous year. Furthermore, Innovent's Shanghai Global R&D Center has been awarded LEED Gold certification by the U.S. Green Building Council, reflecting its commitment to eco-friendly practices.
